

# Get Data Out technical documentation: Treatment for Bladder, Urethra, Renal Pelvis, and Ureter; Bone cancer; Kaposi Sarcoma; Kidney; Oesophageal and Stomach; Sarcoma; and Soft Tissue and Peripheral Nerve cancer

GDO 0020, 2020-03-05

## Background

The fact of treatment with resection, chemotherapy, and radiotherapy is defined as a “yes/no” binary indicator for each malignant cancer registered in the initial treatment period. Three variables indicate whether any resection, chemotherapy, or radiotherapy was received. There are also 8 mutually exclusive variables that indicate the combination of resection, chemotherapy, and radiotherapy received.

### 1. Datasets used

The AV2017.AV\_TREATMENT\_TABLE\_1316\_4P5 dataset in CASREF01 and the end of year AV2017.AV\_TUMOUR dataset are used to produce these figures. The methodology for creating AV2017.AV\_TREATMENT\_TABLE\_1316\_4P5 is detailed in the [CAS-SOP #4.5 linking treatment tables](#).

- AV2017.AV\_TUMOUR was used to select the cohort, tumour and demographic details as well as provide links to other datasets via the ID fields.
- AV2017.AV\_TREATMENT\_TABLE\_1316\_4P5 was used to identify treatments for the tumours in the cohort captured by the cancer registry, Inpatient Hospital Episodes Statistics, the Radiotherapy Datasets collected by NATCANSAT, and the Systematic Anti-Cancer Therapy dataset (see [SOP](#) for details).

## 2. Cohort

The cohort was created in line with the GDO incidence figure metrics, which in turn are generated from the standard restrictions in the counting cases SOP. The cohort was created from the end of year AV2017.AV\_TUMOUR dataset. The cohort was defined as detailed on the [Get Data Out website](#).

To be included in the cohort the following applies:

- Status of registration is final
- Country code is E
- Sex is either male or female
- The deduplication flag is set to 1
- The age is feasible (i.e. between 0 – 200 years)

Cases not meeting the above criteria are excluded from the cohort. Once the restrictions have been applied the cohort is refined using diagnosis year and site codes to select the relevant cohort of interest.

Additionally, treatment data was only defined for ICD-10 C-coded tumours so D-coded tumours were excluded, and no statistic is produced for groups of D-coded tumours. This also meant that proportions could not be calculated for mixed groups that included both D-coded tumours and C-coded. This spans bladder, urethra, renal pelvis, and ureter; kidney; and sarcoma groupings.

Where data cannot be calculated because the group includes D-coded tumours, this is denoted by this value '.d'.

In some cases, treatment data could not be calculated because surgery codes have not yet been defined by the therapeutics team. This means that while chemotherapy and radiotherapy data can be provided, both individual and combinatory treatments involving surgical resection can not be reported on. This spans bone cancer, Kaposi sarcoma, sarcoma, and soft tissue and peripheral nerve cancer groupings.

Where data cannot be calculated because the group lacks definition of the relevant surgery codes, this is denoted by this value '.m'.

### 3. Definitions of treatments

Treatment with resection, chemotherapy, and radiotherapy was defined in the AV2017.AV\_TREATMENT\_TABLE\_1316\_4P5 dataset. The timeframe after diagnosis to include as part of a patient's first course of treatment varies by cancer site and treatment. Resections were also defined using a list of OPCS4 codes, agreed with clinicians. These are detailed in [CAS-SOP #4.5 linking treatment tables](#). The 8 mutually exclusive variables were calculated from the figures in AV\_TREATMENT\_TABLE\_1316\_4P5.

### 4. Variation from published figures

Treatment figures for bladder, urethra, renal pelvis and ureter; bone cancer; Kaposi sarcoma; kidney; oesophageal and stomach; sarcoma; and soft tissue and peripheral nerve cancer have not previously been published by GDO. The definitions of bladder, urethra, renal pelvis and ureter; kidney; oesophageal and stomach; and sarcoma differ from previously published treatment data. For more information, see the supporting information for incidence figures for each cancer site on the [Get Data Out website](#).

### 5. Other caveats

The cohort included tumours diagnosed from 2013-2017. Figures for 2017 diagnoses could not yet be included as data are not yet available for this year. Data for 2017 diagnoses is marked missing with 'a'.

Where a group size is very small, data are not available as a measure to protect patient confidentiality. This is indicated with 'k'.

"Other care" represents the group of patients who had no record of chemotherapy, tumour resection, or radiotherapy in the time frame assessed. This may include patients who received other treatments (such as hormonal therapy or management of symptoms), treatment outside of the time frame assessed, treatment in a private setting, or there may be data missing from the datasets used.

Any questions, please contact [sean.mcphail@phe.gov.uk](mailto:sean.mcphail@phe.gov.uk) or [charlotte.eversfield@phe.gov.uk](mailto:charlotte.eversfield@phe.gov.uk).